Impact of HIV infection, highly active antiretroviral therapy, and hepatitis C coinfection on serum interleukin-27

AIDS. 2010 Jun 1;24(9):1371-4. doi: 10.1097/QAD.0b013e3283391d2b.

Abstract

A newly described cytokine, interleukin-27 (IL-27), that activates naive CD4 T cells, has recently been shown to be an anti-HIV cytokine. However, the effect of HIV infection on IL-27 expression has not been characterized. We found that clinical characteristics, including HIV viral load, hepatitis C virus coinfection, and CD4 T cell counts, were associated with changes in serum IL-27. Overall, our results suggest circulating HIV may suppress IL-27, a critical concept in treatment development with this cytokine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • CD4-Positive T-Lymphocytes
  • HIV Infections / blood*
  • HIV Infections / drug therapy
  • HIV-1*
  • Hepatitis C / blood*
  • Hepatitis C / drug therapy
  • Humans
  • Interleukin-17 / blood*
  • Viral Load

Substances

  • Interleukin-17